Get the Stockscreener App
0.50
0.00%
0.00
Ovid Therapeutics Inc stock is traded at $0.50, with a volume of 535.06K.
It is up +0.00% in the last 24 hours and up +58.23% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$0.50
Open:
$0.4879
24h Volume:
535.06K
Relative Volume:
0.37
Market Cap:
$35.55M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.6667
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
-19.16%
1M Performance:
+58.23%
6M Performance:
-24.63%
1Y Performance:
-49.49%
1-Day Range:
$0.4785
$0.5106
1-Week Range:
$0.4785
$0.634
52-Week Range:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.50 | 35.55M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Will Ovid Therapeutics Inc. price bounce be sustainableFree Fast Gaining Stock Screener Report - Newser
Is Ovid Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
Short interest data insights for Ovid Therapeutics Inc.Summary of Reliable Long-Term Trade Models - Newser
What technical models suggest about Ovid Therapeutics Inc.’s comebackHigh Accuracy Trade Setup Identification - Newser
Is Ovid Therapeutics Inc. stock overvalued or undervaluedExpert Picks Alerts For Beginners - jammulinksnews.com
What makes Ovid Therapeutics Inc. stock price move sharplyReal-Time AI Sentiment and Price Forecast - Newser
Is Ovid Therapeutics Inc. stock poised for growthTrade Setup Builder with Custom Alerts - Newser
Multi asset correlation models including Ovid Therapeutics Inc.Free Secure Capital Picks With Upside Potential - Newser
Combining price and volume data for Ovid Therapeutics Inc.Buy Strategy with Smart Exit Timing - Newser
Identifying reversal signals in Ovid Therapeutics Inc.Low Volatility Stock Analysis With Confidence - Newser
Is it the right time to buy Ovid Therapeutics Inc. stockStock Market Entry Points To Watch Now - jammulinksnews.com
Why Ovid Therapeutics Inc. stock attracts strong analyst attentionBear Market Safe Zone Technical Analysis - Newser
Quantitative breakdown of Ovid Therapeutics Inc. recent moveDaily Exit and Entry Price Prediction - Newser
Ovid Therapeutics Inc. Stock Support and Resistance Levels You Should KnowWeekly Gain Forecast with Momentum Indicators - Newser
Institutional Tools Highlight Unusual Flow in Ovid Therapeutics Inc.Breakout Momentum Picks With Protection Outlined - metal.it
Analyzing Ovid Therapeutics Inc. with multi timeframe chartsConsistent Profit Signals with AI Models - Newser
Published on: 2025-07-29 00:10:51 - metal.it
Should I hold or sell Ovid Therapeutics Inc. stock in 2025Wealth Building Report With Proven Results - jammulinksnews.com
Ovid Therapeutics Inc (OVID) Stock: A Comprehensive 52-Week Review - investchronicle.com
Using R and stats models for Ovid Therapeutics Inc. forecastingBuy and Hold Return Summary with Charts - Newser
How Ovid Therapeutics Inc. stock performs during market volatilityEarnings Impact and Stock Reaction Analysis - Newser
How does Ovid Therapeutics Inc. compare to its industry peersOutstanding risk-reward balance - jammulinksnews.com
What is the dividend policy of Ovid Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com
What are analysts’ price targets for Ovid Therapeutics Inc. in the next 12 monthsMaster stock selection with insider knowledge - jammulinksnews.com
Using R and stats models for Ovid Therapeutics Inc. forecasting 7-Day Equity Return Range Forecast Model - Newser
How strong is Ovid Therapeutics Inc. company’s balance sheetGet daily expert analysis for smarter investing - jammulinksnews.com
Key External Factors That Drive Ovid Therapeutics Inc. Stock Price MovementsReal Time Stock Signal - metal.it
Why is Ovid Therapeutics Inc. stock attracting strong analyst attentionGain insights from top financial experts - jammulinksnews.com
Does Ovid Therapeutics Inc. stock perform well during market downturnsPhenomenal investment performance - jammulinksnews.com
Published on: 2025-07-27 23:38:13 - jammulinksnews.com
Ovid Therapeutics Inc. Company Revenue and Profit Trends: A Deep DivePredictable Return Stock Picks - Newser
How many analysts rate Ovid Therapeutics Inc. as a “Buy”Achieve rapid portfolio appreciation - jammulinksnews.com
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):